BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 10614636)

  • 1. Actions of neuropeptide Y on the rat adrenal cortex.
    Renshaw D; Thomson LM; Carroll M; Kapas S; Hinson JP
    Endocrinology; 2000 Jan; 141(1):169-73. PubMed ID: 10614636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide Y (NPY)- and vasoactive intestinal peptide (VIP)-induced aldosterone secretion by rat capsule/glomerular zone could be mediated by catecholamines via beta 1 adrenergic receptors.
    Bernet F; Bernard J; Laborie C; Montel V; Maubert E; Dupouy JP
    Neurosci Lett; 1994 Jan; 166(1):109-12. PubMed ID: 8190350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
    Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
    Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review).
    Spinazzi R; Andreis PG; Nussdorfer GG
    Int J Mol Med; 2005 Jan; 15(1):3-13. PubMed ID: 15583821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors.
    Jain MR; Pu S; Kalra PS; Kalra SP
    Endocrinology; 1999 Nov; 140(11):5171-7. PubMed ID: 10537146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro steroidogenic effects of neuropeptide Y (NPY1-36), Y1 and Y2 receptor agonists (Leu31-Pro34 NPY, NPY18-36) and peptide YY (PYY) on rat adrenal capsule/zona glomerulosa.
    Bernet F; Maubert E; Bernard J; Montel V; Dupouy JP
    Regul Pept; 1994 Aug; 52(3):187-93. PubMed ID: 7800851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
    Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
    J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide-Y family of peptides in the autocrine-paracrine regulation of adrenocortical function.
    Nussdorfer GG; Gottardo G
    Horm Metab Res; 1998; 30(6-7):368-73. PubMed ID: 9694565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors.
    Kempná P; Körner M; Waser B; Hofer G; Nuoffer JM; Reubi JC; Flück CE
    Mol Cell Endocrinol; 2010 Jan; 314(1):101-9. PubMed ID: 19699258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions of vasoactive intestinal peptide on the rat adrenal zona glomerulosa.
    Hinson JP; Puddefoot JR; Kapas S
    J Endocrinol; 1999 Apr; 161(1):51-7. PubMed ID: 10194528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells.
    DiMaggio DA; Farah JM; Westfall TC
    Endocrinology; 1994 Feb; 134(2):719-27. PubMed ID: 8299567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
    Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
    J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPY regulates catecholamine secretion from human adrenal chromaffin cells.
    Cavadas C; Silva AP; Mosimann F; Cotrim MD; Ribeiro CA; Brunner HR; Grouzmann E
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5956-63. PubMed ID: 11739470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices.
    King PJ; Widdowson PS; Doods HN; Williams G
    J Neurochem; 1999 Aug; 73(2):641-6. PubMed ID: 10428060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
    Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
    Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular neuropeptide Y Y1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA.
    Modin A; Malmström RE; Meister B
    Neuropeptides; 1999 Aug; 33(4):253-9. PubMed ID: 10657500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPY receptor subtype in the rabbit isolated ileum.
    Félétou M; Nicolas JP; Rodriguez M; Beauverger P; Galizzi JP; Boutin JA; Duhault J
    Br J Pharmacol; 1999 Jun; 127(3):795-801. PubMed ID: 10401572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropeptide Y induced attenuation of catecholamine synthesis in the rat mesenteric arterial bed.
    Westfall TC; Naes L; Gardner A; Yang CL
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):723-8. PubMed ID: 16810071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the receptor response for the neuropeptide Y-evoked suppression of parasympathetically-mediated contractions in the guinea pig trachea.
    Grundemar L
    Regul Pept; 1997 Aug; 71(2):97-101. PubMed ID: 9416991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.